12th Dec 2006 14:43
Synergy Healthcare PLC12 December 2006 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY ORINDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE AVIOLATION OF THE RELEVANT LAWS IN THAT JURISDICTION 12 December 2006 INCREASED RECOMMENDED OFFER BY BREWIN DOLPHIN SECURITIES LTD ("BREWIN DOLPHIN") ON BEHALF OF SYNERGY HEALTHCARE PLC "SYNERGY HEALTHCARE") FOR ISOTRON PLC ("ISOTRON") INCREASED RECOMMENDED OFFER DOCUMENT POSTED Further to its announcement of 6 December 2006, Synergy Healthcare announcesthat the offer document (the "Increased Recommended Offer Document") containingthe full terms and conditions of the Increased Recommended Offer for Isotron hastoday been posted to Isotron shareholders, together with the related Form ofAcceptance. Copies of the documents posted today by Synergy Healthcare may be inspected(during normal business hours only on any weekday) at the offices of TaylorWessing, Carmelite, 50 Victoria Embankment, Blackfriars, London EC4Y 0DXthroughout the period during which the Increased Recommended Offer remains openfor acceptance. Enquiries: Synergy Healthcare plc 01332 387 100Richard Steeves, Chief ExecutiveIvan Jacques, Group Finance Director Brewin Dolphin Securities Ltd 0845 270 8600(financial adviser and broker to Synergy Healthcare plc)Mark BradyMatt DavisAndrew Emmott Financial Dynamics 0207 269 7156(PR adviser to Synergy Healthcare plc)David Yates Isotron plc 01793 891 891John Barker, Chief ExecutivePaul Wynne, Finance Director JPMorgan Cazenove Ltd 020 7588 2828(financial adviser and broker to Isotron plc)Mark BreuerMichael Wentworth-StanleyJames MitfordAndrew Truscott Hudson Sandler 020 7796 4133(PR adviser to Isotron plc)Alistair Mackinnon-MussonNicola Savage This announcement does not constitute or form part of, an offer or invitation topurchase or subscribe for any securities. The Increased Recommended Offer willbe made solely by means of the Increased Recommended Offer Document and the Formof Acceptance accompanying the Offer Document, which contains the full terms andconditions of the Increased Recommended Offer including details of how it may beaccepted. Brewin Dolphin is acting for Synergy Healthcare and for no-one else inconnection with the Increased Recommended Offer and will not regard any otherperson as its client nor be responsible to anyone other than Synergy Healthcarefor providing the protections afforded to clients of Brewin Dolphin nor forproviding advice in relation to the Increased Recommended Offer or any matterreferred to in this announcement. Brewin Dolphin is authorised and regulated bythe Financial Services Authority. JPMorgan Cazenove, which is authorised and regulated in the United Kingdom bythe Financial Services Authority, is acting exclusively for Isotron and no oneelse in connection with the Increased Recommended Offer and will not beresponsible to anyone other than Isotron for providing the protections offeredto clients of JPMorgan Cazenove or for providing advice in relation to mattersreferred to in this announcement. Under the provisions of Rule 8.3 of the City Code, if any person is, or becomes"interested" (directly or indirectly) in one per cent or more of any class of"relevant securities" of Isotron or Synergy, all "dealings" in any relevantsecurities of the relevant company (including by means of an option in respectof, or a derivative referenced to, any such "relevant securities") must bepublicly disclosed by no later than 3.30p.m. on the Business Day following thedate of the relevant transaction. This requirement will continue until the dateon which the Increased Recommended Offer becomes, or is declared, unconditionalas to acceptances, lapses or is otherwise withdrawn or on which the "offerperiod" otherwise ends. If two or more persons act together pursuant to anagreement or understanding, whether formal or informal, to acquire an "interest"in "relevant securities" of Isotron, they will be deemed to be a single personfor the purpose of Rule 8.3 of the City Code. Under the provisions of Rule 8.1 of the City Code, all "dealings" in "relevantsecurities" of Isotron by Synergy Healthcare or Isotron, or by any of theirrespective "associates", must be privately and publicly disclosed by no laterthan 12.00 noon on the Business Day following the date of the relevanttransaction. If you are in any doubt as to the application of Rule 8 to you, please contactan independent financial adviser authorised under the Financial Services andMarkets Act 2000, consult the Panel's website at www.thetakeoverpanel.org.uk orcontact the Panel on telephone number +44 20 7382 9026, fax +44 20 7236 7005. A disclosure table, giving details of the companies in whose "relevantsecurities" "dealings" should be disclosed, and the number of such securities inissue, can also be found on the Panel's website. The availability of the Increased Recommended Offer to Isotron Shareholders whoare not resident in the United Kingdom may be affected by the laws of therelevant jurisdictions in which they are located. Persons who are not residentin the United Kingdom should inform themselves about, and observe, applicablelegal or regulatory requirements of their jurisdiction. The Increased Recommended Offer will not be made, directly or indirectly, in orinto, or by use of the mails, or by any means or instrumentality (including,without limitation, telex, facsimile transmission, telephone, internet or otherforms of electronic communication) of interstate or foreign commerce of, or byany facilities of a national securities exchange of, the United States, Canada,Australia, South Africa or Japan or any other jurisdiction if to do so wouldconstitute a violation of the relevant laws of such jurisdiction and theIncreased Recommended Offer cannot be accepted by any such use, means orinstrumentality or otherwise from or within the United States, Canada,Australia, South Africa or Japan or any other jurisdiction if to do so wouldconstitute a violation of the relevant laws of such jurisdiction. Accordingly,copies of this announcement are not being, and must not be, mailed or otherwiseforwarded, distributed or sent in or into or from any such jurisdiction. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SYR.L